source
- Ultra-low dose nivolumab shows survival benefit for head and neck cancer patients in IndiaResearchers presented data at the American Society of Clinical Oncology meeting showing that an ultra‑low dose of the PD‑1 inhibitor nivolumab, given with chemotherapy, extended survival for patien…
- Revolution Medicines begins shipping experimental pancreatic cancer drug daraxonrasib under FDA early access programRevolution Medicines announced that it has started sending its experimental pancreatic cancer therapy, daraxonrasib, to doctors and patients through an FDA‑authorized early access program. The comp…STAT · 5mo agoRegulatoryPositive